Tilray, Inc. (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the second quarter ended June 30, 2020.All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Aphria vs. Tilray @themotleyfool #stocks $TLRY $APHA. An analyst at Jefferies thinks both have fallen enough—for now. Today, we'll look at which of the two leading companies in the marijuana sector, Aphria (NASDAQ:APHA) and Tilray (NASDAQ:TLRY), is a better buy right now. The company is also doing great in achieving profitability, with a net income of CA$5.7 million during the quarter. The problem with TLRY stock is that it doesn’t offer any such reason. Finally, Northland Securities reiterated a hold rating on shares of Tilray in a report on Tuesday, August 11th. U.S. States With Legal Recreational Marijuana Use in 2020, Investment Radar — Top CBD Stocks to Watch. The company ranks above Tilray in many aspects, including better profit margins, the ability to raise cash in difficult times, and a greater production capacity. Year-to-date, the stock is down 66.7%. Copyright © What Can You Expect from Marijuana Stocks in April? Tilray is a global leader in cannabis research, cultivation, processing and distribution. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Tilray (NASDAQ:TLRY) had a disastrous 2019—the stock lost 75.7% of its value. Corporate insiders own 16.75% of the company’s stock.
As for production capacity, Aphria sold 14,014 kilograms of cannabis products with an average selling price of CA$5.46 per gram g for adult-use cannabis and CA$6.41 per gram g for medical cannabis, which declined overall but was offset by a more than 98% increase in terms of total capacity. Is Tilray the Hottest Growth Stock to Buy Now? Tilray has a 12-month low of $2.43 and a 12-month high of $29.50. But sales in the first half of 2020 totaled just $14 million. California Public Employees Retirement System lifted its holdings in shares of Tilray by 363.1% during the second quarter. During the earnings call, Tilray mentioned that it raised $60 million in debt as a capital cushion to survive financial difficulties. Nasdaq Tilray has partnerships with 17,000 retailers in 20 countries, and clinical trials are ongoing as it works to expand its medical marijuana products into prescription drugs. I am a statistician with a knack for analyzing clinical trials and company financials. The U.S., at least at the federal level, hasn’t opened up at all. First, it’s not fast enough. Currently, it only has $174 million in cash and equivalents on its balance sheet, at a burn rate of $80 million per quarter. Matthew McCall left Wall Street to actually help investors — by getting them into the world’s biggest, most revolutionary trends BEFORE anyone else. [CDATA[/* >